Neoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Radiation for Rectal Cancer

Preoperative Radiotherapy Combined with Capecitabine Chemotherapy in Chinese Patients with Locally Advanced Rectal Cancer

“…The pCR rate ranged from 7% to 31% in most of the previously reported studies with capecitabine and RT, 14,[21][22][23][24][25][26][27][28][29][30] and FOLFOX and radiation therapy and 5-FU and radiation therapy up to a level of 18-25%. [31][32][33][34] The pCR rate in the current study (13.6%) is comparable to those found by Kim 14 The higher figures in these studies in comparison to the present study may be due to a more favorable distribution of the T stage, 22 the use of a radiation boost to the tumor, or the use of leucovorine in addition to capecitabine. 14 These discordant results may be due to differences in staging of the primary tumor; as we know, EUS seems to provide more accurate staging for mobile T1 and T2 lesions, whereas MRI seems to be superior for fixed, more locally advanced disease.…”

Chimioradiothérapie préopératoire du cancer du rectum : expérience d’un centre

“…À l'inverse, la capécitabine s'est révélée non inférieure au 5-fluoro-uracile en perfusion continue en association avec une radiothérapie concomitante, dans notre étude tout comme dans l'étude de Hofheinz et al [20]. D'autres molécules de chimiothérapie sont également en cours d'étude : l'irinotécan, en association avec le 5-fluoro-uracile [21][22][23], et des thérapies ciblées comme le cétuximab (inhibiteurs du récepteur de l'epidermal growth factor) ou le bévacizumab (dirigé contre le vascular endothelial growth factor) [24][25][26][27][28][29][30] ont donné dans plusieurs études de phase I/II des résultats encourageants en termes de taux de réponse complète histologique et de toxicité.…”

Phase II study of preoperative bevacizumab, capecitabine, and radiotherapy for resectable locally advanced rectal cancer.

“…All of these studies had the expectation of improving the pathological complete response rate to therapy as a surrogate marker of the improvement in disease and overall survival [10,[14][15][16][17][18][19][20][21][22][23][24]. Table 5 shows a summary of studies containing bevacizumab which have been published so far.…”